Novo Nordisk Investor Presentation - First Nine Months of 2016
Financial results
-
Investor presentation
First nine months of 2016
Slide 16
first nine months of 2016
DKK million
Sales
Gross profit
9M 2016
82,208
69,943
Gross margin
Sales and distribution costs
Percentage of sales
Research and development costs
Percentage of sales
85.1%
(20,468)
24.9%
Administration costs
Percentage of sales
Other operating income, net
Non-recurring income¹
Operating profit
37,226
Operating profit adjusted for non-recurring income¹
37,226
Financial items (net)
(370)
(10,093)
12.3%
(2,796)
3.4%
640
(9,574)
(2,693)
3.4%
3,388
2,825
38,319
35,494
(5,150)
4%
N/A
(3%)
7%
(93%)
9M 2015
79,051
67,471
Change
4%
4%
85.4%
(20,273)
1%
25.6%
5%
12.1%
Profit before income tax
36,856
33,169
11%
Tax
Effective tax rate
Net profit
(7,630)
(6,567)
16%
20.7%
19.8%
29,226
Diluted earnings per share (DKK)
11.50
26,602
10.28
10%
12%
Diluted earnings per share (DKK) adjusted for partial divestment of NNIT
11.50
9.40
22%
changing
diabetes
1 Non-recurring income comprises the partial divestment of NNIT (DKK 2,376 million) and out-licensing of assets for inflammatory disorders (DKK 449 million), both in 2015View entire presentation